INTERNATIONAL JOURNAL OF
PHARMACEUTICAL AND HEALTHCARE INNOVATION
journal homepage: www.ijphi.com

OPEN ACCESS

Review Article

Advances in Drug Delivery Systems for the Central Nervous System: Overcoming the Blood-Brain Barrier

Vijay Sharma*[1], Amit Kumar[2] , Alankar Shrivastav[1], Pawan Singh[1], Deepak Singh Chaudhary[1], Navneet Verma[1]

[1]Faculty of Pharmacy, IFTM University, Moradabad, U.P

[2]Shri Ramswaroop Memorial University, Lucknow U.P

Article Info

Article history:

Manuscript ID:

IJPHI2213202025
Received: 22-November -2024
Revised :13- January -2024
Accepted: 20- January 2025
Available online: January 2025

Keywords:
Blood-brain barrier, drug delivery systems, nanoparticles, focused ultrasound, receptor-mediated transport, neurodegenerative diseases, CNS drug delivery.

Corresponding Author:
vijaysrampur@gmail.com

Abstract

A dynamic and selective barrier, the blood-brain barrier (BBB) strictly controls the flow of chemicals from the bloodstream into the central nervous system (CNS). Although the BBB protects the body from dangerous infections and poisons, it also poses a major obstacle to the creation of efficient medications for neurological conditions. Recent developments in drug delivery systems (DDS) that attempt to cross the blood-brain barrier and enable targeted delivery of therapeutic drugs to the brain are the main topic of this study. We investigate a number of tactics, such as chemical approaches like receptor-mediated transcytosis and liposomal encapsulation, physical techniques like focused ultrasound and microbubble-assisted disruption, and the application of nano-materials like nano-particles and dendrimers to improve drug permeability. We also look at cutting-edge strategies like brain-targeted viral vectors and intranasal delivery, which completely circumvent the BBB by using different pathways or by using brain-specific targeting ligands. The review also emphasizes the present drawbacks and difficulties of these methods, including the requirement for exact control over drug release, variable targeting efficiency, and toxicity issues. Lastly, we go over the possible therapeutic uses of these sophisticated DDS, such as the management of brain tumors, psychiatric conditions, and neurodegenerative diseases like Parkinson's and Alzheimer's. These new drug delivery techniques present encouraging opportunities for the creation of safer and more efficient therapies for CNS illnesses by bridging the gap between preclinical research and clinical translation.

Introduction

The blood-brain barrier (BBB) functions as a highly selective filter that limits the passage of drugs and other therapeutic agents into the central nervous system (CNS). While this barrier plays a crucial protective role, it also poses significant challenges in the management of neurological conditions such as Alzheimer's disease, Parkinson's disease, brain tumors, and stroke. Despite notable progress in drug development, the BBB significantly hampers the effectiveness of most therapeutics aimed at the CNS by obstructing their access to the brain. Consequently, finding ways to circumvent the BBB is a primary challenge in the field of neuropharmaceutical research (1). Recent innovations in drug delivery systems (DDS) are designed to address this issue by enabling the direct delivery of therapeutic compounds to the brain. This chapter will examine advanced DDS technologies and strategies that have been developed to either bypass or temporarily disrupt the BBB, thereby enhancing the delivery of medications for the treatment of CNS disorders. We will also discuss the mechanisms underlying the BBB, the types of DDS currently in development, and their potential applications in clinical settings (2).

Mechanisms of the Blood-Brain Barrier

The blood-brain barrier (BBB) is a highly selective and protective physiological structure that serves as a critical interface between the blood circulation and the brain (Figure 1). At its core, the BBB is primarily composed of endothelial cells that form the walls of the blood vessels within the brain. These endothelial cells are tightly interconnected by specialized structures known as tight junctions. Tight junctions prevent the passive diffusion of large, hydrophilic (water-soluble) molecules, thus acting as a robust filter to restrict the entry of potentially harmful substances, such as pathogens, toxins, and metabolic waste products, from the bloodstream into the brain (3).However, the function of the BBB extends beyond merely blocking harmful compounds. It also serves to regulate the entry of essential nutrients and ions, maintaining a highly controlled environment that is critical for the brain's normal function. The BBB allows the selective passage of nutrients, such as glucose and amino acids, and ions like potassium and calcium, which are vital for neuronal activity, while preventing the unregulated flow of other substances that could disrupt brain homeostasis. These vital nutrients and ions are transported across the BBB by specific membrane transporters and ion channels that operate through active or facilitated mechanisms (4).

In addition to the endothelial cells, other cellular components contribute to the barrier's function and integrity. Astrocytes, a type of glial cell, provide crucial support through their end-feet, which envelop the blood vessels and release signaling molecules that help regulate endothelial cell function and tight junction formation. Pericytes, contractile cells surrounding the capillary endothelium, also play a significant role by influencing endothelial cell permeability and maintaining vascular stability. Additionally, the extracellular matrix (ECM) surrounding the BBB components provides structural support and further regulates the interactions between these cells. Together, these cellular and extracellular components work synergistically to maintain the integrity and functionality of the BBB, ensuring it can perform its dual role of protecting the brain from harmful agents while facilitating the transport of essential molecules (5,6).



Figure 1: Digramatic representation of Blood Brain Barrier

The precise regulation of the BBB is essential for sustaining brain homeostasis; however, it also poses challenges for the effective delivery of pharmaceutical agents aimed at treating central nervous system disorders (7).The selective permeability of the BBB is significantly affected by efflux pumps, such as P-glycoprotein, which actively expel a variety of drugs from the brain. This section will elucidate the molecular and cellular mechanisms that form the BBB and explore potential

strategies to manipulate or circumvent these barriers to enhance drug delivery to the central nervous system (8).

Table 1: Overview of Drug Delivery Strategies for Overcoming the Blood-Brain Barrier[9]

Delivery System	Mechanism of Action	Examples/Applications	Challenges
Nanoparticles and Nanomaterials	Surface modification for receptor-mediated transport	Liposomes, dendrimers, solid lipid nanoparticles	Targeting specificity, scaling up production
Focused Ultrasound & Microbubbles	Temporary disruption of BBB with ultrasound energy	Treatment for brain tumors, Alzheimer's	Safety concerns, localized inflammation
Receptor-Mediated Transcytosis	Targeting BBB receptors for drug transport	Transferrin receptor targeting	Limited receptor availability, off-target effects
Intranasal Drug Delivery	Direct transport through olfactory and trigeminal nerves	Peptides, small molecules	Limited to small and lipophilic drugs
Viral Vectors	Gene and drug delivery via viral mechanisms	AAV vectors for gene therapy	Immunogenicity, limited cargo capacity

Drug Delivery Systems for Crossing the Blood-Brain Barrier

Innovative drug delivery systems (DDS) are essential for overcoming the blood-brain barrier (BBB), as they must either disrupt or circumvent this barrier to enable the effective transport of medications into the brain. Recent years have seen the emergence of several promising drug delivery strategies (table 1).

Nanoparticles and Nanomaterials

Nanoparticles have become one of the most promising strategies for drug delivery to the central nervous system (CNS) due to their diminutive size, extensive surface area, and capacity to encapsulate a diverse range of therapeutic agents, including small molecules, peptides, and nucleic acids. Various types of nanoparticles, such as liposomes, dendrimers, and solid lipid nanoparticles (figure 2), can be modified on their surfaces with targeting ligands (e.g., transferrin, antibodies) to facilitate receptor-mediated transport across the blood-brain barrier (BBB). This section will explore the different types of nanoparticles utilized in drug delivery, their mechanisms of action, as well as their respective advantages and limitations (10).



Figure 2: Nanoparticles and Nanomaterials

Table 2: Nanoparticle-Based Drug Delivery Systems for CNS Disorders

Nanoparticle Type	Targeted Disorder	Delivery Mechanism	References
Liposomes	Alzheimer's, Parkinson's	PEGylation for BBB penetration	Barenholz, 2012
Dendrimers	Brain tumors, Stroke	Targeting with antibodies or ligands	Li et al., 2016
Solid Lipid Nanoparticles	Epilepsy, Neuroinflammation	Surface functionalization for BBB targeting	Sánchez et al., 2013

Focused Ultrasound and Microbubbles

Focused ultrasound (FUS) in conjunction with microbubbles offers a promising non-invasive technique for temporarily disrupting the blood-brain barrier (BBB), enabling therapeutic agents to penetrate the brain. This is particularly important in treating neurological disorders, where the BBB typically prevents many drugs from reaching their targets in the brain. By using high-frequency sound waves, FUS focuses energy on specific areas of the brain, while microbubbles, injected into the bloodstream, oscillate in response to the ultrasound waves. This oscillation creates cavitation, which temporarily opens the tight junctions between the endothelial cells of the BBB, allowing drugs, biologics, and even gene therapies to cross into the brain. The disruption is reversible, typically lasting only a few minutes, after which the BBB returns to its normal, protective state (11).Research has demonstrated the effectiveness of FUS for delivering a range of therapeutic agents, including chemotherapy drugs, monoclonal antibodies, and gene therapies. In preclinical studies, FUS has been successfully used to deliver drugs to targeted areas of the brain in animal models, including small molecules like temozolomide for brain tumors, as well as larger biologics such as amyloid-targeting antibodies for Alzheimer's disease. Notably, studies by Hynynen et al. (2005) showed that FUS could effectively open the BBB in non-human primates, paving the way for future clinical applications. In clinical trials, this technique has shown promise for enhancing drug delivery to patients with glioblastoma, Parkinson's disease, and Alzheimer's disease, among others. For example, MRI-guided FUS can target specific brain regions to treat tumors or deliver therapies to affected regions in neurodegenerative diseases (12).The potential applications of FUS are most apparent in treating brain tumors and neurodegenerative disorders. For brain tumors, especially glioblastoma, FUS enables the delivery of chemotherapy directly to the tumor site, bypassing the BBB and increasing the drug concentration within the tumor while minimizing systemic side effects. This method has the potential to improve patient outcomes by overcoming the limitations of traditional therapies. Similarly, in neurodegenerative diseases like Alzheimer's and Parkinson's, FUS could facilitate the delivery of drugs like amyloid-targeting monoclonal antibodies or neuroprotective agents, potentially slowing disease progression and alleviating symptoms(13)

However, despite its promise, several challenges remain. The long-term safety of repeated FUS treatments needs further investigation, as there are concerns about potential tissue damage or changes in brain function. Additionally, optimizing FUS parameters, such as ultrasound intensity, frequency, and duration, is crucial to improve the efficiency and precision of drug delivery. Tailoring these factors to individual patients and their specific conditions will be necessary to maximize therapeutic benefit (figure 3). Further studies are also required to refine the method for better targeting and minimizing off-target effects (14).



Figure 3: Focused ultrasound (FUS) in conjunction with microbubbles

Receptor-Mediated Transcytosis

Receptor-mediated transcytosis utilizes intrinsic receptors present on the blood-brain barrier (BBB) to enable the delivery of pharmaceuticals into the brain. Notably, the transferrin receptor and low-density lipoprotein receptor have been identified as targets for transporting drugs across the BBB (figure 4). This method entails the conjugation of therapeutic agents to ligands that selectively bind to these receptors, thereby facilitating effective transport across the BBB. This section will explore the different receptors employed in this technique, the categories of drugs being administered, and the challenges associated with receptor-specific targeting (15, 16].



Figure 4: Receptor-mediated transcytosis

Intranasal Drug Delivery

Intranasal drug administration offers a means to bypass the blood-brain barrier (BBB) by allowing therapeutic agents to be delivered directly to the brain via the olfactory and trigeminal pathways. This method facilitates the entry of medications into the central nervous system (CNS) without the need to cross the BBB. Recent studies have highlighted the efficacy of intranasal delivery for small molecules, peptides, and even gene therapies (Illum, 2000). This review will explore the mechanisms that govern intranasal drug transport, its current applications, and the challenges involved in improving this delivery method (17).

Brain-Targeted Viral Vectors

Viral vectors, especially adeno-associated virus (AAV) vectors, have been engineered to serve as vehicles for gene therapies and drug administration. AAV vectors have demonstrated encouraging outcomes in their ability to traverse the blood-brain barrier (BBB) and facilitate the delivery of therapeutic genes or small molecules to the brain (Sands et al., 2001). This section will examine the application of viral vectors in surmounting the BBB, the specific central nervous system (CNS) disorders being addressed, and the challenges associated with viral-based delivery systems (18).

Innovative Drug Delivery Systems under Development

In addition to the aforementioned approaches, several new DDS are under development to enhance the delivery of drugs to the brain. These include:

Smart Nanocarriers: Nanoparticles engineered to deliver their therapeutic agents in reaction to particular stimuli, such as pH levels, temperature variations, or enzymatic activity, are referred to as smart nanocarriers. These systems facilitate the controlled release of drugs, which may lead to a decrease in side effects and an enhancement of the drug's therapeutic effectiveness (19).

Exosome-Mediated Delivery: Exosomes are extracellular vesicles capable of traversing the blood-brain barrier (BBB) naturally, and they have been investigated as vehicles for drug delivery owing to their biocompatibility and capacity to encapsulate a diverse array of therapeutic agents. This section will examine the potential of exosomes in drug delivery, highlighting their benefits as well as the challenges that accompany their application (20).

Challenges and Limitations in BBB Drug Delivery

Despite the promising advances in DDS, several challenges remain in effectively and safely delivering therapeutics across the BBB. These challenges include:

Toxicity and Safety: Temporary disruption of the blood-brain barrier (BBB), while showing potential benefits, is associated with risks including localized inflammation and possible harm to brain tissue (Cai et al., 2015). It is essential to conduct thorough clinical trials to evaluate the safety profiles of different drug delivery systems (DDS), especially nanoparticles(21).

Targeting Specific Brain Regions: The accomplishment of targeted drug delivery to particular areas of the brain continues to pose a considerable challenge. The variability in the blood-brain barrier (BBB) structure, along with the heterogeneity of central nervous system (CNS) disorders, complicates the accurate delivery of drugs (22).

Scalability and Clinical Translation: Although DDS strategies demonstrate potential in animal studies, the transition of these technologies to clinical applications presents significant challenges. Concerns regarding drug manufacturing, expenses, and sustained effectiveness need to be resolved before these approaches can be widely adopted as standard treatments for neurological disorders (23).

Clinical Applications and Future Directions

This section will examine the clinical applications of sophisticated drug delivery systems, focusing on the management of neurodegenerative disorders such as Alzheimer's and Parkinson's disease, as well as brain tumors and stroke. Additionally, we will investigate the future trajectories of drug delivery system research, particularly in the realm of personalized medicine, which has the potential to facilitate more customized and effective therapeutic approaches. Moreover, the role of artificial intelligence (AI) in enhancing drug delivery system optimization will be addressed, highlighting its

potential to improve targeting, drug release mechanisms, and overall patient outcomes(24).

Conclusion

This chapter will conclude with a summary of the significant progress made in drug delivery systems aimed at overcoming the blood-brain barrier, their prospective clinical applications, and the challenges that still persist. We will highlight the necessity for ongoing innovation in drug delivery systems to enhance the treatment of central nervous system disorders and will explore the future of drug delivery within the framework of personalized and precision medicine.

Acknowledgments

The author would like to thank to Director, HRIT University, Ghaziabad and IFTM University, Moradabad for encouraging research work. The author is also profoundly grateful to my supervisor and co-supervisor for their kind support and guidance.

Funding Sources

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

The authors do not have any conflict of interest.

Data Availability Statement

This statement does not apply to this article.

Ethics Statement

This research did not involve human participants, animal subjects, or any material that requires ethical approval.

Informed Consent Statement

This study did not involve human participants, and therefore, informed consent was not required.

References

1. Kadry H, Noorani B, Cucullo L. A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020;17:69.
2. Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, Okoroafor CC, Eze SC, Kalu OL, Odoh EC, Nwadike UG, Ogbodo JO, Umeh BU, Ossai EC, Nwanguma BC. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023 Jun 24;9(6). doi: 10.1016/j.heliyon.2023.e17488. PMID: 37416680; PMCID: PMC10320272.
3. Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015 Jan 5;7(1) PMID: 25561720; PMCID: PMC4292164.
4. Kadry H, Noorani B, Cucullo L. A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020;17:69.
5. Zidarič T, Gradišnik L, Velnar T. Astrocytes and human artificial blood-brain barrier models. Bosn J Basic Med Sci. 2022 Sep 16;22(5):651-672. PMID: 35366791; PMCID: PMC9519155.
6. Wu D, Chen Q, Chen X, et al. The blood–brain barrier: Structure, regulation and drug delivery. Sig Transduct Target Ther. 2023;8:217.
7. Saraiva C, Praça C, Ferreira R, et al. Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34-47.
8. Demeule M, Régina A, Jodoin J, et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol. 2002 Jun;38(6):339-348. PMID: 12529928.
9. Yetisgin AA, Cetinel S, Zuvin M, et al. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020 May 8;25(9):2193.. PMID: 32397080; PMCID: PMC7248934.
10. Ekhator C, Qureshi MQ, Zuberi AW, et al. Advances and opportunities in nanoparticle drug delivery for central nervous system disorders: A review of current advances. Cureus. 2023 Aug 29;15(8:; PMCID: PMC10463100.
11. Burgess A, Hynynen K. Drug delivery across the blood-brain barrier using focused ultrasound. Expert Opin Drug Deliv. 2014 May;11(5):711-721. doi: 10.1517/17425247.2014.897693. Epub 2014 Mar 20. PMID: 24650132; PMCID: PMC4388327.
12. Arif WM, Elsinga PH, Gasca-Salas C, et al. Focused ultrasound for opening blood-brain barrier and drug delivery monitored with positron emission tomography. J Control Release. 2020;324:303-316.
13. Hersh AM, Bhimreddy M, Weber-Levine C, et al. Applications of focused ultrasound for the treatment of glioblastoma: A new frontier.

Cancers (Basel). 2022 Oct 8;14(19):4920. 0. PMID: 36230843; PMCID: PMC9563027.

14. Burgess A, Shah K, Hough O, Hynynen K. Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert Rev Neurother. 2015 May;15(5):477-491. PMID: 25936845; PMCID: PMC4702264.
15. Pulgar VM. Transcytosis to cross the blood brain barrier, new advancements and challenges. Front Neurosci. 2019 Jan 11;12:1019. PMID: 30686985; PMCID: PMC6337067.
16. Niazi SK. Non-invasive drug delivery across the blood-brain barrier: A prospective analysis. Pharmaceutics. 2023 Nov 7;15(11):2599. PMID: 38004577; PMCID: PMC10674293.
17. Hanson LR, Frey WH 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008 Dec 10;9 Suppl 3(Suppl 3). PMID: 19091002; PMCID: PMC2604883.
18. Wang JH, Gessler DJ, Zhan W, et al. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Sig Transduct Target Ther. 2024;9:78.
19. Yetisgin AA, Cetinel S, Zuvin M, et al. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020 May 8;25(9):2193. PMID: 32397080; PMCID: PMC7248934.
20. Huang J, Xu Y, Wang Y, et al. Advances in the study of exosomes as drug delivery systems for bone-related diseases. Pharmaceutics. 2023 Jan 9;15(1):220. McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS. Temporary disruption of the blood-brain barrier by use of ultrasound and micro bubbles: Safety and efficacy evaluation in rhesus macaques. Cancer Res. 2012 Jul 15;72(14):3652-3663. PMCID: PMC3533365.
21. Partridge B, Eardley A, Morales BE, et al. Advancements in drug delivery methods for the treatment of brain disease. Front Vet Sci. 2022 Oct 18;9:1039745.
22. Coelho JF, Ferreira PC, Alves P, et al. Drug delivery systems: Advanced technologies potentially applicable in personalized treatments. EPMA J. 2010 Mar;1(1):164-209.
23. Gadhave DG, Sugandhi VV, Jha SK, et al. Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance. Ageing Res Rev. 2024;99:102357.